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Abstract
The ability of Bifidobacterium longum to use intestinal mucus as a metabolizable
source was characterized. Bifidobacterium longum biotype longum NCIMB8809
was grown in a chemically semi-defined medium supplemented with human
intestinal mucus, and the cytoplasmic protein profiles and several glycosyl
hydrolase activities were analysed and compared with those obtained from the
same bacterium grown in the absence of mucus. We were able to identify 22
different proteins in the cytoplasmic fraction, of which nine displayed a different
concentration in the presence of mucus. Among the proteins whose concentrations
varied, we found specific enzymes that are involved in the response to different
environmental conditions, and also proteins that mediate interaction with mucus
in bacteria. Significant changes in some glycoside-hydrolysing activities were also
detected. In addition, stable isotope labelling of amino acids in cell culture
demonstrated that B. longum incorporates leucine from the glycoprotein matrix
of mucin within its proteins. This study provides the first proteomic data regarding
the interaction of B. longum with intestinal mucus, and contributes to the
understanding of the behaviour of this intestinal species in its natural ecological
niche.
Introduction
Microorganisms of the genus Bifidobacterium are common
inhabitants of the human gastrointestinal tract, constituting
one of the predominant microorganisms in the colon during
the early stages of life (Harmsen et al., 2000; Lay et al., 2005).
Because of the health-promoting effects attributed to some
strains of this genus, these bacteria are attractive probiotic
candidates and they are routinely included in functional
food products, mainly dairy products, in which they are
present as adjunct cultures (Masco et al., 2005; Salminen
et al., 2005). Furthermore, several studies have demon-
strated that apart from being present in the luminal or the
faecal community, bifidobacterial populations are also
abundant among the mucosa-adherent community (Guei-
monde et al., 2007; Leitch et al., 2007; Turroni et al.,
2009a, b). Some Bifidobacterium strains have been shown to
display exocellular glycosidases potentially acting on sugar
chains of mucin glycoproteins. In particular, Bifidobacterium
bifidum possesses an arsenal of enzymatic activities, includ-
ing endo-a-N-acetylgalactosaminidases and a-L-fucosidases,
that are likely to be involved in mucus degradation at the
intestinal level (Katayama et al., 2004, 2005; Ruas-Madiedo
et al., 2008). Some of these enzymes are also present in other
Bifidobacterium species, such as Bifidobacterium longum and
Bifidobacterium breve, likely contributing to a partial degra-
dation of the glycoprotein matrix of mucus (Ruas-Madiedo
et al., 2008).
Bacteria that are able to multiply at the expense of mucus
display an adaptative advantage to survive in the colon. In a
previous report, we were able to demonstrate that B. longum
NCIMB8809 was able to partially degrade mucin from
porcine stomach (Ruas-Madiedo et al., 2008). In the present
study, we aim to analyse the capacity of this strain to use
human intestinal mucus as a metabolizable energy source,
and to investigate in-depth the proteins and enzymatic
activities that could be involved in the interactions between
B. longum and mucus.
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Materials and methods
Microorganisms and growth conditions
Bifidobacterium longum NCIMB 8809 (National Collection
of Industrial and Marine Bacteria, Aberdeen, Scotland, UK),
a potential probiotic able to produce antimicrobial sub-
stances and originally isolated from nursling stools, was
used as a model microorganism for this study (O’Riordan &
Fitzgerald, 1998). The preinoculum was obtained by cultur-
ing the strain on MRSc agar plates [MRSc: MRS broth
(Difco) supplemented with 0.05% (w/v) L-cysteine
(Merck)]. Subsequently, an isolated colony was transferred
to MRSc broth and grown overnight. The culture was
washed three times with a semi-defined medium for B.
longum (SDMBL) (Coute´ et al., 2007), and inoculated at
0.05% in the same medium with, or without, human
intestinal mucus. For stable isotope labelling of amino acids
in cell culture (SILAC) experiments, 13C6-leucine was used
as the labelled amino acid in the SDMBL medium, and the
experiments were carried out exactly as described by Coute´
et al. (2007). The working concentration of mucus in the
SDMBL medium was 0.4mg total proteinmL1 (Ouwehand
et al., 2002). The human intestinal mucus had been collected
from the healthy part of resected colonic tissue as described
previously (Ouwehand et al., 2002). The mucus was dis-
solved in HEPES–Hanks buffer (10mM HEPES, pH 7.4)
and stored at  20 1C until use. Incubations were carried
out at 37 1C in an anaerobic chamber (Don Whitley
Scientific, West Yorkshire, UK) in an atmosphere of 80%
N2, 10% H2, 10% CO2, or, alternatively, in anaerobic jars
(Anaerocult A System; Merck). At least three different
biological replicates were performed for each condition.
Two-dimensional electrophoresis (2DE) and
quantitative proteomic analysis
Variations in the level of cytoplasmic protein concentrations
of B. longum cells grown in the presence of mucus were
analysed by a 2DE study. We used a pI range between 4 and
7, which theoretically allows the separation of about two-
thirds of the total proteome of B. longum (Sa´nchez et al.,
2008). In all the experiments, cells were collected in the early
stationary phase of growth (OD600nm 0.5–0.9). Cell-free
protein extracts were obtained as described previously (Ruiz
et al., 2009a). For 2DE analysis, 500mg of protein from B.
longum NCIMB8809 extracts were loaded onto a strip with
an immobilized pH range of 4 to 7 (GE Healthcare) and
focused at 65 000V h1. Separation in the second dimension
was carried out in 12.5% polyacrylamide-sodium dodecyl
sulphate gels and protein spots were visualized with colloi-
dal Coomassie staining. Proteins were identified by peptide
mass fingerprinting and matrix-assisted laser desorption
ionization/time of flight/MS at the Proteomics Unit of the
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Fig. 1. 13C6-leucine incorporation by Bifidobacterium longum NCIMB8809 in the presence and absence of mucus. Representative mass spectra from
peptides resulting from digestion of the proteins Xfp and Tal are shown. The arrows indicate the presence of light peptide forms (LP) containing one
12C6-Leu and one
13C6-Leu.
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Parque Cientı´fico de Madrid (Cantoblanco, Madrid, Spain).
Protein identification was achieved by combining MS data
to search a nonredundant protein database (NR; 4.106
entries; National Center for Biotechnology Information)
using the MASCOT software (Matrix Science). Spot detection,
volume quantification and statistical analysis were per-
formed using IMAGEMASTER PLATINUM software (version 5.00,
GE Healthcare). Three protein extracts, coming from three
independent cultures, were obtained for each condition
(mucus absence or mucus presence), and at least three
independent gels (technical replicates) were performed for
each extract.
Determination of enzymatic activities and
organic acid production
Enzymatic activities were measured for the cytoplasmic
fraction and for the secreted fraction. Cell-free protein
extracts from the cytoplasmic fraction were obtained as
described above. The supernatants were collected by centri-
fugation from cells grown to the early stationary phase,
concentrated 10 times using VivaSpin Columns (cutoff
3000 kDa, Sartorius), and filtered through 0.22-mm sterile
filters. Glycosidase activities were measured spectrophotome-
trically from the release of p-nitrophenol (pNP) produced by
the enzymatic hydrolysis of the corresponding pNP-glycoside
substrates (Sigma), as described previously (Ruiz et al.,
2009b). One unit of enzymatic activity was defined as the
amount of protein that releases 1 nmol pNPmin1. Specific
activities were determined in duplicate for each culture, and
expressed as units per milligram protein. For organic acid
determination, Bifidobacterium cultures, grown in the ab-
sence or presence of mucus, were collected by centrifugation.
Cells were removed from the suspension, and the supernatant
was analysed by HPLC according to Ruas-Madiedo et al.
(2005), to quantify lactic, acetic and pyruvic acids, as well as
glucose and fructose.
Results and discussion
Previous studies demonstrated that B. longum NCIMB8809
showed significant differences in growth when cultivated in
a chemically defined medium in the presence of porcine
mucin, displaying a higher growth after 48 h of incubation
when compared with mucin absence conditions (Ruas-
Madiedo et al., 2008). This suggested to us that this strain
could also display some ability to use human intestinal
mucin as a metabolizable source. In fact, when a similar
experiment was performed, we showed that, after overnight
growth, B. longum NCIMB 8809 reached lower ODs at
600 nm in the absence of, rather than in the presence of,
mucus (data not shown), suggesting that the presence of
mucus in the growth medium provides an extra energy
source that allows the bacterium to reach a higher OD.
The human intestinal mucus layer plays an important
role in preventing adhesion and binding by enteropathogens
and toxins, and it consists mainly of water (c. 95%) and
glycoproteins (1–10%) (Hamer et al., 2009). The glycopro-
tein matrix serves as a nutrient for bacterial growth in the
intestine, and numerous bacterial species have been shown
to display metabolic activities capable of degrading the
complex links between carbohydrates and proteins, or with-
in them, including B. bifidum, Bacteroides fragilis and
Akkermansia muciniphila (Derrien et al., 2004; Macfarlane
et al., 2005; Ruas-Madiedo et al., 2008). In order to
determine whether amino acids present in the glycoprotein
matrix of mucin can be taken up and incorporated into the
proteins synthesized by B. longum during growth in SDMBL
broth, SILAC experiments were performed as described by
Coute´ et al. (2007). Bifidobacterium longum NCIMB8809
was grown for 13 generations in SDMBL broth and the
presence of heavy and light leucine in B. longum proteins
was detected by MS. The percentage of light peak height on
heavy peak height was 1.30 0.05 times higher with mucus
for peptides containing one leucine, and the percentage of
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Fig. 2. 2D gels showing the proteins expressed by Bifidobacterium
longum NCIMB8809 in SDMBL medium without (a) and with (b) human
mucus. Spot codes refer to the proteins in Table 1. MM, molecular mass.
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medium peak height on heavy peak height was 1.75 0.09
times higher with mucus for peptides containing two
leucines, suggesting that the bacterium is utilizing other
leucine sources different from the one provided by the
labelled amino acid (Coute´ et al., 2007). As an example,
Fig. 1 shows the spectra of two peptides [from the enzymes
xylulose-5-phosphate/fructose-6-phosphate phosphoketo-
lase (Xfp) and transaldolase (Tal)], in which the presence of
light peptides (containing one 12C6-Leu and one
13C6-Leu)
is significantly higher when the cells were grown in the
presence of human mucus, indicating the incorporation of
mucus-derived leucine.
In order to analyse the influence of human intestinal
mucus on the cytoplasmic protein profiles of B. longum
NCIMB8809, a 2DE analysis was carried out. Twenty spots
(Fig. 2) were selected on the basis of their apparent variation
of cytoplasmic concentrations, and the proteins were identi-
fied using MS (Table 1). Among the proteins, whose expres-
sion was affected by the presence of mucus, it is worth
pointing out the lower concentration of a putative elonga-
tion factor Ts. This protein associates with the elongation
factor Tu during protein translation in the ribosome, but
they can also be displayed on the surface of the bacteria,
where they have been reported to act as mediators of
adhesion processes to mucins (Granato et al., 2004; Wu
et al., 2008). Ketol acid reductoisomerase 1, a protein
involved in the synthesis of branched chain amino acids
(BCAAs), significantly increased its concentation as a re-
sponse to the presence of mucus. BCAAs are the most
abundant amino acids in membrane proteins, and it is
known that many membrane proteins are induced in
bacteria as a response to mucus (Ruas-Madiedo et al., 2008;
Tu et al., 2008), suggesting an enrichment of BCAA-reach
proteins, likely membrane proteins, in the presence of mucus.
Furthermore, ribose 5-phosphate isomerase (RpiA) was dras-
tically overproduced in the presence of mucus. RpiA is an
enzyme that catalyses the interconversion between ribose-
5-phosphate and ribulose-5-phosphate in the pentose phos-
phate pathway. These data suggest that the carbohydrate
preferences of B. longum could change when mucus is present
in the medium, and could indicate a shift in the carbohydrate
catabolism of this bacteria, which prompted us to determine
some glycosyl hydrolase activities, the glucose consumption
and the abundance of some secondary metabolites.
Table 1. Identification of Bifidobacterium longum NCIMB8809 proteins affected by the presence of mucus
Spot
no. Putative function Gene Accession no. Mass pI
No. of
peptides
matched Coverage
Normalized
volume ratio
BL 1 Hypothetical protein in DPS family gi|23465202 17765 4.57 10 52% —
BL 2 Ketol-acid reductoisomerase 1 ilvC1 Q8G6V2|ILVC1_BIFLO 38707 5.10 18 54% ""
BL 3 Elongation factor Ts tsf Q8G485|EFTS_BIFLO 29961 5.07 19 64% ###
BL 4 = BL 5 DNA polymerase sliding clamp
subunit (PCNA homolog)
gi|23335940 40999 4.54 14 48% ###
BL 6 Threonine synthase thrC gi|23465602 54293 4.63 17 41% —
BL 7 Hypothetical protein BL0121 gi|23464747 50596 4.66 18 59% ###
BL 8 Ribosomal protein S1 gi|23336678 54397 9.19 26 55% —
BL 10 ABC_NikE_OppD_transporters dppD gi|23465950 73291 5.91 30 55% #
BL 11 CTP synthase pyrG Q8G5X7|PYRG_BIFLO 61344 5.40 30 62% ###
BL 12 Predicted GTPase obg gi|23336705 61284 5.15 25 52% —
BL 13 Dihydroxy-acid dehydratase ilvD Q8G3H2|ILVD_BIFLO 67199 5.28 20 42% —
BL 14 Acetate kinase ackA gi|23465540 44287 5.47 22 57% —
BL 15 Sugar kinases, ribokinase family kdgK gi|23335430 32547 4.88 25 75% —
BL 16 Response regulator with putative
antiterminator output domain
amiR gi|23336562 29134 4.85 14 49% —
BL 17 Predicted redox protein, regulator
of disulfide bond formation
gi|23336616 15161 5.32 7% "
BL 18 Protein-tyrosine-phosphatase wzb gi|23336613 19944 5.49 8% ###
BL 19 Chorismate synthase aroC gi|23465452 42337 6.06 20 70% —
BL 20 Elongation factor P efp gi|23464692 20698 5.05 9 61% —
BL 21 Ribose 5-phosphate isomerase rpiA gi|23336290 25281 4.83 13 59% """
BL 22 Methionine aminopeptidase map gi|23466277 28589 4.91 14 60% —
Spot numbers refer to the proteins labelled in Fig. 2. Putative functions were assigned from the KEGG pathways for Bifidobacterium longum NCC2705.
Coverage is given by the number of tryptic peptides observed contributing to the percentage of amino acid coverage. Normalized volume ratios are
given for each protein derived from cells cultured in the absence of human mucus, with respect to the protein derived from cells cultured with mucus.
One arrow indicates an increase (or a decrease) of 1.7–2.5-fold in spot intensity, two arrows indicate an increase (or decrease) of 2.5–5-fold and three
arrows indicate an increase (or a decrease) of more than fivefold or proteins undetected in the presence of mucus. –, not differentially expressed.
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Enzymatic activities were determined for the cytoplasmic
fraction and for the secreted fraction (Table 2). We detected
some minor changes in b-D-galactopyranosidase, a-L-arabino-
furanosidase, N-acetyl-b-D-glucosaminidase, a-D-galactopyra-
nosidase and b-D-xylopyranosidase activities. Remarkably,
the N-acetyl-b-D-glucosaminidase activity showed a reduction
in the cytoplasmic protein extracts, and an increase in the
extracellular milieu, when the cells were grown in the
presence of mucus. BacterialN-acetyl-b-D-glucosaminidases
are glycoprotein-degrading enzymes that have been related
to the colonization of mucus environments (Homer et al.,
1994; Karamanos et al., 1995). The increase of the secreted
activity in the presence of mucus could support the possible
role of this enzyme in mucus degradation.
Finally, we found a significant increase in the glucose
consumption of cells grown in the presence of mucus
(295.43 19.38mg of glucose consumed in 100mL), in
relation to those conditions in which mucus was not present
(226.71 23.70mg of glucose consumed in 100mL). Con-
sistent with an activation of the glucose catabolism in the
presence of mucus, we also detected a higher production of
lactic and acetic acids when mucus was present in the
growth medium (50.78 5.02mg 100mL1 of lactic acid
and 85.14 7.96mg 100mL1 of acetic acid in the absence
of mucus; 78.62 4.95mg 100mL1 of lactic acid and
115.13 4.83mg 100mL1 of acetic acid in the presence of
mucus).
In summary, we found that human mucus influences the
metabolism of B. longum biotype longum NCIMB8809 in a
semi-defined medium. Concomitantly, an increase of glu-
cose consumption was observed, together with a shift of
glycosidase activities that could play a role in the degrada-
tion of the glycoprotein matrix of mucin. Furthermore,
mucin-associated leucine was incorporated into the B. long-
um proteins during growth, and some proteins that are
likely to mediate interaction with mucus, as well as some
others involved in the response to environmental challenges,
were found to be differentially produced. The results shown
here will contribute to understanding the interactions
between human mucus and intestinal Bifidobacterium.
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